[1] 林海龙. 动脉粥样硬化性心血管病的一级预防:预防斑块与血栓,谁更重要?[J].中华高血压杂志, 2021, 29(1):4.
[2] Stone PH, Libby P, Boden WE.Fundamental Pathobiology of Coronary Atherosclerosis and Clinical Implications for Chronic Ischemic Heart Disease Management-The Plaque Hypothesis: A Narrative Review[J].JAMA Cardiol, 2023, 8(2):192-201.
[3] Catapano AL, Graham I, De Backer G, et al.2016ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR)[J]. Athe-rosclerosis, 2016, 253: 281-344.
[4] Nissen S E, Tuzcu E M, Schoenhagen P, et al.Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.[J]. JAMA, 2004, 291(5):1071-1080.
[5] Cholesterol, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials[J]. Lancet, 2010, 376(9753):1670-1681.
[6] Collins R, Reith C, Emberson J, et al.Interpretation of the evidence for the efficacy and safety of statin therapy[J].Lancet, 2016, 388(10059):2532-2561.
[7] Lemstra M, Blackburn D, Crawley A, et al.Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis[J]. CJC, 2012, 28(5):574-580.
[8] Mancini GB, Baker S, Bergeron J, et al.Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)[J]. CJC, 2016, 32(7 Suppl):S35-S65.
[9] HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatmentHPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment[J]. Eur Heart J, 2013, 34(17):1279-1291.
[10] Abifadel M, Varret M, Rabès JP, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nat Genet, 2003, 34(2):154-156.
[11] Benjannet S, Rhainds D, Essalmani R, ea al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol[J]. J Biol Chem, 2004, 279(47):48865-48875.
[12] Zhang DW, Lagace TA, Garuti R, et al.Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation[J]. J Biol Chem, 2007, 282(25):18602-18612.
[13] Yamamoto T, Lu C, Ryan RO.A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor[J]. J Biol Chem, 2011, 286(7):5464-5470.
[14] Lo Surdo P, Bottomley MJ, Calzetta A, et al.Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH[J]. EMBO Reports, 2011, 12(12):1300-1305.
[15] Cohen J, Pertsemlidis A, Kotowski IK, Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9[J]. Nat Genet, 2005, 37(2):161-165.
[16] Leren TP.Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia[J]. Clin Genet, 2004, 65(5):419-422.
[17] Basiak M, Kosowski M, Cyrnek M, et al.Pleiotropic Effects of PCSK-9 Inhibitors[J]. Int J Mol Sci, 2021, 22(6):3144.
[18] Sabatine MS, Giugliano RP, Keech AC, et al.Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease[J]. N Engl J Med, 2017, 376(18):1713-1722.
[19] O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk[J]. Circulation, 2019, 139(12):1483-1492.
[20] Rosenson RS, Hegele RA, Fazio S, et al.The Evolving Future of PCSK9 Inhibitors[J]. J Am Coll Cardiol, 2018, 72(3):314-329.
[21] Schwartz GG, Steg PG, Szarek M, et al.Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome[J]. N Engl J Med, 2018, 379(22):2097-2107.
[22] Nicholls SJ, Kataoka Y, Nissen SE, et al.Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction[J]. JACC Cardiovasc Imaging, 2022, 15(7):1308-1321.
[23] Räber L, Ueki Y, Otsuka T, et al.Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial[J]. JAMA, 2022, 327(18):1771-1781.
[24] Kini AS. Effect of evolocumab on coronary plaque characteristics in stable coronary artery disease: a multimodality imaging study (the YELLOW Ⅲ study)[J]. Presented at:ACC/WCC2023, March 4, 2023. New Orleans, LA.
[25] Wright RS, Ray KK, Raal FJ, et al.Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis[J]. J Am Coll Cardiol March 4, 2021, 77(9):1182-1193.
[26] Ray KK, Wright RS, Kallend D, et al.Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol[J]. N Engl J Med, 2020, 382(16):1507-1519.
[27] Raal FJ, Kallend D, Ray KK, et al.Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia[J]. N Engl J Med, 2020, 382(16):1520-1530.
[28] Fire A, Xu S, Montgomery MK, et al.Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J]. Nature, 1998,391(6669):806-11.
[29] Wilson RC, Doudna JA.Molecular mechanisms of RNA interference[J]. Annu Rev Biophys, 2013, 42:217-239.
[30] Lam JK, Chow MY, Zhang Y, et al.siRNA Versus miRNA as Therapeutics for Gene Silencing[J]. Mol Ther Nucleic Acids, 2015, 4(9):e252.
[31] Dyrbuś K, Gąsior M, Penson P, et al.Inclisiran-New hope in the management of lipid disorders?[J] J Clin Lipidol, 2020, 14(1):16-27.
[32] 英克司兰临床应用中国专家建议制定组,等[J].中华心血管病杂志(网络版), 2024, 7: e1000161(2024-04-30).
[33] RS Wright, FJ Raal, W Koenig, et al. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients[J]. Data presented at the ESC Congress, 2023.
[34] 霍勇,李勇, 韩雅君,等.Inclisiran亚洲研究ORION18中国大陆人群亚组分析,第34届长城心脏病学大会摘要, Poster GW34-c0796.
[35] Ray KK, Troquay RPT, Visseren FLJ, et al.Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial[J]. Lancet Diabetes Endocrinol, 2023, 11(2):109-119.
[36] 王雅玲,刘剑,张冬颖.前蛋白转化酶枯草溶菌素9抑制剂在心血管疾病中的研究进展[J].心血管病学进展, 2019,(2):208-212.
[37] Yano H, Horinaka S, Ishimitsu T.Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome[J]. J Cardiol, 2020, 75(3):289-295.
[38] Kokina B, Trusinskis K, Lapsovs M,et al.Inclisiran-containing low-density lipoprotein cholesterol reduction effectively stabilizes atherosclerotic plaques[J].European Heart Journal, 2024(Supplement_1).
[39] Kataoka T, Uzui H, Morishita T,et al.Very short-term effects of single dose of proprotein convertase subtilisin kexin 9 inhibitor therapy before percutaneous coronary intervention[J].European Heart Journal, 2024(Supplement_1).
[40] Nicholls SJ, Puri R, Anderson T, et al.Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial[J]. JAMA, 2016, 316(22):2373-2384.
[41] Ogata A, Oho K, Matsumoto N, et al.Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab[J]. Acta Neurochir (Wien), 2019, 161(3):597-600.
[42] 2024 ESC—A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Characteristics in People with Asymptomatic High-Risk Carotid Stenosis: SLICE-CEA CardioLink-8 Primary Results.
[43] 中国心血管健康与疾病报告编写组,胡盛寿.中国心血管健康与疾病报告2022概要[J].中国循环杂志, 2023, 38(6):583-612.
[44] 中国血脂管理指南修订联合专家委员会,李建军,赵水平,等.中国血脂管理指南(2023年)[J].中国循环杂志, 2023, 38(3):237-271. |
